Drug Trial Radar · NCT07230418
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes
Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Nov 10, 2025
Primary completion
Apr 19, 2026
Study completion Apr 19, 2026
Sponsor
- Lead sponsor
- Chengdu Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HRS-3095 oral administration in healthy subjects. This study will also explore food effect and the effect of HRS-3095 on CYP3A4 metabolic enzymes.
Conditions
- Chronic Spontaneous Urticaria
Interventions
HRS-3095 TabletDrug
Oral HRS-3095 tablet.
HRS-3095 Placebo TabletDrug
Oral HRS-3095 placebo tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: Up to 21 days.
- Incidence of serious adverse events (SAEs)Time frame: Up to 21 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Frist Clinical Medicial College of Qingdao University
Qingdao, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.